Jul 22, 2021

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights

Jun 30, 2021

Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference

May 20, 2021

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

May 13, 2021

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

May 10, 2021

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

May 7, 2021

Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results

Apr 30, 2021

Oncolytics Biotech® Announces Annual General Meeting

Apr 29, 2021

Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting

Apr 12, 2021

Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study

Apr 12, 2021

Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting